Clinical Trial Update: Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of Botulinum Toxin A for Raynaud phenomenon secondary to systemic sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• Botulinum toxin A (botulinum toxin type A)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Status: COMPLETED